Posted by Michael Wonder on 12 May 2026
Sironax’s SARM1 inhibitor SIR2501 granted FDA fast track designation in chemotherapy-induced peripheral neuropathy
11 May 2026 - Sironax today announced that the US FDA has designated its SARM1 inhibitor SIR2501 as a fast track product for chemotherapy-induced peripheral neuropathy.
SIR2501 is a first in class allosteric inhibitor of SARM1, a key driver of nerve damage in a broad range of neurological diseases.
